Analytical Data
-
Gene name
ERVK-5
- Application
-
Alternative Names
HERV-K(II) Gag protein (HERV-K_3q12.3 provirus ancestral Gag polyprotein) (Gag polyprotein)
-
Species
Human
-
Source
E. coli
-
Tag
N- His & C- Myc
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q9HDB9
-
Expression Region
2-667aa
-
Molecular Weight
80.9 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
ERVK-5 is a member of the Endogenous Retrovirus K (ERVK) family, which has gained attention in recent years due to its potential role in various biological processes and diseases. Originating from ancient retroviral infections in human ancestors, ERVK genes, including ERVK-5, can influence immune responses, cell differentiation, and tumorigenesis. Researchers have been particularly interested in the expression patterns of ERVK-5 in different tissues, as well as its potential contributions to the pathogenesis of diseases such as cancer and autoimmune disorders. Recent studies have highlighted the dual functionality of ERVK-5, showing that it can both promote and inhibit tumor growth, depending on the cellular context. Moreover, its expression has been associated with poor prognosis in certain cancer types, making it a potential biomarker for disease progression. The ability to create recombinant ERVK-5 proteins has opened up new avenues for understanding its molecular mechanisms and interactions. Investigating these recombinant proteins is crucial for elucidating the role of ERVK-5 in various physiological and pathological contexts, and could facilitate the development of novel therapeutic strategies targeting ERVK-5 related pathways. Thus, research into ERVK-5 not only deepens our understanding of human biology but also holds promise for innovative approaches in disease management and treatment.
